Category Press Releases

WuXi Biologics Unveils WuXiHigh™ 2.0 for Ultra-Concentrated Biologics

WuXi Biologics Launches WuXiHigh™ 2.0 to Advance High-Concentration Biologic Formulations WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the official launch of WuXiHigh™ 2.0, a next-generation, high-throughput formulation development platform specifically engineered for…

Read MoreWuXi Biologics Unveils WuXiHigh™ 2.0 for Ultra-Concentrated Biologics

WuXi AppTec’s Nantong Facility Honored with 2025 Architizer A+Award for Seamlessly Integrating Technology and Human-Centered Design

WuXi AppTec’s Nantong Facility Wins 2025 Architizer A+Award for Excellence in Human-Centered Industrial Design WuXi AppTec, a globally recognized provider of research, development, and manufacturing services for the pharmaceutical and life sciences industries, has proudly announced that its Nantong facility…

Read MoreWuXi AppTec’s Nantong Facility Honored with 2025 Architizer A+Award for Seamlessly Integrating Technology and Human-Centered Design

U.S. FDA Grants Orphan Drug Designation to Riliprubart for Treating Antibody-Mediated Rejection in Solid Organ Transplant Recipients

Sanofi’s Riliprubart Receives U.S. FDA Orphan Drug Designation for Antibody-Mediated Rejection in Solid Organ Transplantation The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to riliprubart, an investigational immunology therapy developed by Sanofi, for the treatment…

Read MoreU.S. FDA Grants Orphan Drug Designation to Riliprubart for Treating Antibody-Mediated Rejection in Solid Organ Transplant Recipients